Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUE-102 in Recurrent Glioblastoma
NCT06917885Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Immunotoxins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CUE-102 in glioblastoma (GBM). Primary endpoints: Dose-limiting-toxicities at 3 weeks and Maximum Tolerated Dose at 3 weeks. Started Jul 2025; status: recruiting.
02
Drugs
CUE-102
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06917885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917885.